JP3981467B2 - Magnesium hydrogen citrate hydrate and process for producing the same - Google Patents
Magnesium hydrogen citrate hydrate and process for producing the same Download PDFInfo
- Publication number
- JP3981467B2 JP3981467B2 JP14250498A JP14250498A JP3981467B2 JP 3981467 B2 JP3981467 B2 JP 3981467B2 JP 14250498 A JP14250498 A JP 14250498A JP 14250498 A JP14250498 A JP 14250498A JP 3981467 B2 JP3981467 B2 JP 3981467B2
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- water
- hydrogen citrate
- citric acid
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HSXLIRULMXTTLM-UHFFFAOYSA-L magnesium;2-(carboxymethyl)-2-hydroxybutanedioate;hydrate Chemical compound O.[Mg+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O HSXLIRULMXTTLM-UHFFFAOYSA-L 0.000 title claims description 43
- 238000000034 method Methods 0.000 title description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 119
- 239000013078 crystal Substances 0.000 claims description 86
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 68
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000011777 magnesium Substances 0.000 claims description 32
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 29
- 229910052749 magnesium Inorganic materials 0.000 claims description 28
- 229940091250 magnesium supplement Drugs 0.000 claims description 28
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- DIXGJWCZQHXZNR-UHFFFAOYSA-L magnesium citrate Chemical compound [Mg+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O DIXGJWCZQHXZNR-UHFFFAOYSA-L 0.000 claims description 12
- 159000000003 magnesium salts Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229960005336 magnesium citrate Drugs 0.000 claims description 5
- 239000004337 magnesium citrate Substances 0.000 claims description 5
- 235000002538 magnesium citrate Nutrition 0.000 claims description 5
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 description 35
- 239000007864 aqueous solution Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 24
- 239000007900 aqueous suspension Substances 0.000 description 14
- 239000002994 raw material Substances 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000001095 magnesium carbonate Substances 0.000 description 8
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 8
- 239000000347 magnesium hydroxide Substances 0.000 description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 6
- 229960002303 citric acid monohydrate Drugs 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000000395 magnesium oxide Substances 0.000 description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000011637 magnesium salts of citric acid Substances 0.000 description 3
- 235000019848 magnesium salts of citric acid Nutrition 0.000 description 3
- 150000004686 pentahydrates Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 2
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- WATVKUKXTKWHRP-UHFFFAOYSA-N [K].[Br] Chemical compound [K].[Br] WATVKUKXTKWHRP-UHFFFAOYSA-N 0.000 description 1
- BGMAUVRZRQJJLU-UHFFFAOYSA-L [O-]C(CC(CC([O-])=O)(C(O)=O)O)=O.O.O.O.O.[Mg+2] Chemical compound [O-]C(CC(CC([O-])=O)(C(O)=O)O)=O.O.O.O.O.[Mg+2] BGMAUVRZRQJJLU-UHFFFAOYSA-L 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- -1 citrate ions Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Description
【0001】
【発明の属する技術分野】
本発明は、例えば医薬品原料、工業薬品原料、マグネシウム強化剤などに用いられるクエン酸水素マグネシウム水和物に係り、特に、水に易溶のクエン酸水素マグネシウム水和物、およびその製法に関する。
【0002】
【従来の技術】
一般に、クエン酸のマグネシウム塩としては、クエン酸水素マグネシウムC6 H6 MgO7 とクエン酸マグネシウムC12H10Mg3 O14が挙げられる。それらの殆どは水和物として存在し、その分子式や構造式は非常に複雑であり多岐にわたっている。
かかるクエン酸のマグネシウム塩はいずれも、製造段階においてクエン酸の水溶液または懸濁液中に金属マグネシウムまたはマグネシウム塩類を添加して中和した時点では透明な水溶液となっている。この水溶液に加熱や冷却などの工程を施して結晶を析出させると、その結晶は晶析条件などの違いにより、例えば水和数、クエン酸の数、またはマグネシウムの数が様々である種々の構造式をとる。しかも、それらの殆どは水に対する溶解度が小さく水中で白濁するため、得られた結晶を再び完全に溶かした水溶液として使用することは困難である。
【0003】
他方、日本薬局方外医薬品規格1997、USP official Monographなどによれば、大腸検査・手術における前処置用の内服下剤として、クエン酸水素マグネシウム水和物が液剤(水溶液)の形で使用されている。しかしながら、これらの液剤には経時とともに沈殿を生じ安定性に欠けるものがある。また、液剤であるため、液洩れ防止を考慮した取扱いを講じなければならない。
そこで、日本薬局方外医薬品の別紙規格として、クエン酸水素マグネシウムの散剤が認められている。因みに、クエン酸のマグネシウム塩を製剤として使用する場合には水に可溶性の散剤が使用されるが、かかるものとして例えば非晶質体の無水塩(例えば、特開昭55−108814号、特開平5−194205号などの公報参照)、または結晶体の五水塩(例えば、USP2260004号、特開平6−228046号などの公報参照)が知られている。
【0004】
【発明が解決しようとする課題】
本発明者は、従来周知の非晶質体の無水和物や結晶体の五水塩に限らず、比較的少量の水であっても溶解しやすく、しかも安定なクエン酸水素マグネシウム水和物、およびこれを製造する方法を見出し、また製剤での経時変化も安定していることを調べ、本発明を完成するに至ったのである。
【0005】
【課題を解決するための手段】
本発明は、クエン酸1モル量に対しマグネシウム量として0.6倍モル量以上1.0倍モル量未満の金属マグネシウムまたはマグネシウム塩類をクエン酸と反応させた後、当該反応液を10℃以下に冷却し静置することにより晶析させて得られ、25℃の水100mlに対する溶解度が20g以上であって、式:C6H6MgO7・xH2O(x:3から5までの実数)で表されるクエン酸水素マグネシウム水和物、およびその製法に関する。
【0006】
【発明の実施の形態】
本発明に係るクエン酸水素マグネシウム水和物は、前記したように、クエン酸の水溶液ないし懸濁液に金属マグネシウムまたはマグネシウム塩類を添加して反応させ、当該反応液から生成物を晶析させて得たものである。
本発明に用いられるクエン酸は、クエン酸、無水クエン酸、イソクエン酸のみならず、イソクエン酸の脱水物であるラクトンをも含んでいる。
【0007】
また、本発明に用いられる金属マグネシウムまたはマグネシウム塩類(以下、これらを「マグネシウム原料」という)のうち、マグネシウム塩類は塩基性の塩類であるか酸性の塩類であるかを問わないが、入手容易な塩基性の塩類を用いるのが好都合である。
かかる塩基性の塩類としては、水酸化マグネシウム、炭酸マグネシウム、または酸化マグネシウムなどが挙げられ、そのうち炭酸マグネシウムとしては軽質炭酸マグネシウムや重質炭酸マグネシウムが挙げられる。これらのなかでは、水とのなじみがよく、クエン酸との反応性が高い点から水酸化マグネシウムあるいは重質炭酸マグネシウムを用いることが好ましい。また、水溶液中における反応であることから、マグネシウム塩類の形態としては、特に限定しないが例えば20メッシュパス以下の細かい粒子径を有する粉末であることが、水になじみやすい点で望ましい。
上掲のマグネシウム原料は単独で、または、2種以上を混合して用いることができる。
【0008】
本発明に使用される水としては、できるだけマグネシウム以外の塩類を含めないようにし、かつ、クエン酸水素マグネシウムの純粋な結晶を水から析出させるために、イオン交換水や蒸留水などの精製水を用いることが好ましい。
【0009】
本発明におけるクエン酸は、水溶液ないし懸濁液の状態で用いられる。クエン酸を水に添加する際、水の使用量があまりに少ない場合はクエン酸の水に対する溶解量が小さくなるので、水の量はクエン酸100部(重量部、以下同様)に対して50部以上、好ましくは75部以上とすることが望ましい。逆に、水の使用量があまりに多い場合は、マグネシウム原料を加えた際にクエン酸水素マグネシウムの結晶析出量が少なくなるため、水の使用量はクエン酸100部に対し130部以下とするのが良く、好ましくは100部以下とすることが望ましい。
【0010】
尚、クエン酸の水溶液ないし懸濁液(以下、懸濁水溶液(I)という) は、クエン酸の全量が水に溶解した状態であってもよく、クエン酸の一部が懸濁した状態であってもよく、更には溶解した状態および懸濁した状態が混在した状態であってもよい。但し、反応を十分に進行させ、かつ、均質なクエン酸水素マグネシウム水和物を得るためには、クエン酸の全量が完全に水に溶解している状態であることが好ましい。前記の懸濁水溶液(I)を調整するにあたり、懸濁水溶液(I)の液温は、水に対するクエン酸の溶解度を高めるために、15℃以上とするのがよく、好ましくは25℃程度とすることが望ましい。
【0011】
続いて、懸濁水溶液(I)にマグネシウム原料を撹拌しながら添加することにより、クエン酸とマグネシウムとの反応が進行してクエン酸水素マグネシウム水和物が生成し、クエン酸水素マグネシウム水和物を含有した水溶液ないし懸濁液(以下、懸濁水溶液(II)という)が得られる。
【0012】
本発明におけるマグネシウム原料の使用量は、クエン酸1モル量に対しマグネシウム量として0.6倍モル量以上、好ましくは0.7倍モル量以上、更に好ましくは0.75倍モル量以上であることが望ましい。マグネシウム原料の使用量が0.6倍モル量を下回ると、マグネシウム量が絶対的に不足してクエン酸水素マグネシウム水和物の収量が低下したり、クエン酸が単体で析出したりするので好ましくない。一方、クエン酸水素マグネシウム水和物の品質を向上させ、更にはクエン酸に対する収量の向上化を図るため、マグネシウム原料の使用量は、1倍モル量未満、好ましくは0.98倍モル量以下、更に好ましくは0.95倍モル量以下であることが望ましい。マグネシウム原料の使用量が1倍モル量以上であると、水に対するクエン酸水素マグネシウム水和物の溶解性が極端に小さくなるので好ましくない。
【0013】
本発明においては、クエン酸の懸濁水溶液(I)にマグネシウム原料を添加して反応が進行すると、クエン酸水素マグネシウム水和物の懸濁水溶液(II)が得られる。この反応は終始、酸性域で行われる。更に反応が十分に進行すると、両者はほぼ完全に溶解する。この反応にあたって、懸濁水溶液(I)の温度が低すぎると、クエン酸が完全に溶解せず、その結果反応が完全に進行しない。従って、反応に際して懸濁水溶液(I)の温度が15℃を下回っていることは好ましくなく、好ましいのは20℃以上であり、より好ましくは25℃以上である。逆に、懸濁水溶液(I)の温度が高すぎると、反応の進行が早くなり過ぎて生成物が均質とならず、クエン酸水素マグネシウムの各種水和物やクエン酸マグネシウム(クエン酸2分子とマグネシウム3原子からなる)の各種水和物などの沈殿が生成する。これらの沈殿は水に不溶性である。従って、反応時における懸濁水溶液(I)の温度は60℃以下であることが好ましく、より好ましくは50℃以下であり、更に好ましくは45℃以下である。
【0014】
上記の条件でクエン酸の懸濁水溶液(I)にマグネシウム原料を添加した場合、反応が十分に進行すると懸濁水溶液(II)の濁りがなくなって、無色〜微黄色の透明な水溶液(以下、水溶液(I)という)となる。この水溶液(I)は、pH値が2.5(29℃)〜3.3(21℃)であって、酸性域にある。もし、かかる操作の間に結晶が析出したりあるいは白濁して沈殿が生成した場合、その結晶または沈殿は単体でなく、目的としないものを含んだ結晶や沈殿であることが多い。かかる場合はろ過により除去し、目的とするクエン酸水素マグネシウム水和物と混合しないようにする必要がある。
【0015】
本発明では、クエン酸水素マグネシウムの水溶液(I)から、水に易溶性の結晶を得ることがポイントとなる。そのためには、結晶析出工程および結晶成長工程からなる晶析工程において、水溶液(I)を10℃以下に冷却保持することが肝要となる。この低温の水溶液(I)に種結晶として水溶性のクエン酸水素マグネシウム水和物を、クエン酸仕込み量の0.5〜2.0重量%添加すれば、目的とするクエン酸水素マグネシウム水和物をより収率よく得ることができる。尚、添加する種結晶としては水溶性の無水クエン酸マグネシウムでも構わない。
種結晶の添加後に静かに撹拌すると、水溶液(I)は懸濁液(以下、懸濁液(III) という)となる。この懸濁液(III) を4〜5℃に冷却保持し、25〜50時間静置する。この間、撹拌などによる混合は一切行わないことが肝要である。そうして、結晶が十分に成長し、もはや結晶の析出が認められなくなった時点を晶析工程の終点とする。
【0016】
この間に析出したものは結晶型を有し、白濁の沈殿は混在していない。かかる結晶を得るための好ましい晶析温度は10℃以下である。晶析時の溶液温度が10℃を超えると、次工程で添加する種結晶が溶解して用をなさなくなるので好ましくない。但し、溶液温度は極力低い方がよいが、少なくとも溶液の凍結温度は上回っている必要がある。
因みに、晶析中の懸濁液(III) を撹拌すると、水不溶性の微結晶や白濁した沈殿が析出する。それに対し、本発明では、結晶塊を撹拌することなく十分に静置した後、母液から分離して結晶を取出し粉砕し、送風して乾燥する。尚、好ましい乾燥温度は50℃以下であり、より好ましくは35℃以下であり、最も好ましくは25℃以下である。乾燥温度が50℃を超えると水和数に影響を及ぼし、水に対する結晶の溶解性を低下させるおそれがある。
【0017】
得られた結晶は白〜淡黄色を呈し、低温雰囲気下であっても5倍量以下と比較的少量の水に溶解するクエン酸水素マグネシウム水和物である。このクエン酸水素マグネシウム水和物の水和数は、反応に使用する原料の濃度、すなわちクエン酸イオンとマグネシウムイオンの反応割合および乾燥温度によって若干異なるが、クエン酸水素マグネシウム1モルに対して3〜5(実数)である。
【0018】
上記のように得た結晶は、溶液中の溶質の濃度により、または溶質濃度が一定の場合には冷却温度や、種結晶として添加されるクエン酸水素マグネシウム水和物の組成あるいは当該結晶の乾燥温度などにより、結晶型や水和数などに相違が現れ、その結果、水に対する溶解性も異なっている。
そこで、本発明における反応生成物の晶析にあたっては、仕込み全量に対し、0.02〜0.04重量%の水易溶性のクエン酸水素マグネシウム水和物を、種結晶として低温の飽和水溶液に添加し3〜10℃で静置することにより、目的とするクエン酸水素マグネシウム水和物の結晶を得ることができる。尚、種結晶の添加量は結晶核を形成するに足る量であればよく、できるだけ少ないほうが好ましい。
【0019】
かくして得られた本発明のクエン酸水素マグネシウム水和物は、晶析時の条件により水和数xが異なるが、C6 H6 MgO7 ・xH2 O(x:3から5までの実数)の型を有し、25℃において水100mlに20g以上が溶解して安定した状態(pH=3.5〜4.5)にあり、マグネシウムの含量が8.0〜9.1重量%(水和物換算)である。
【0020】
【実施例】
次に、本発明のクエン酸水素マグネシウム水和物およびその製法を、下記の実施例および比較例に基づいて更に詳しく説明するが、本発明はかかる実施例に限定されるものではない。
【0021】
実施例1.
クエン酸一水和物210gをイオン交換精製水200mlに溶解させ、20〜30℃に保持した。このとき、クエン酸水溶液が懸濁していることもある。このときのクエン酸水溶液のpHは0.5〜0.6であった。このクエン酸水溶液に水酸化マグネシウム45gを撹拌しながら徐々に添加した。水酸化マグネシウムの添加終了後も撹拌を続け十分に反応させた。水酸化マグネシウムを溶解させた後の反応液のpHは2.6であった。この反応液をろ過して得たろ液に、水に易溶性のクエン酸水素マグネシウム水和物の微細結晶2gを種結晶として添加し均等に懸濁させた。この懸濁液を5〜10℃の低温下で4日間静置すると、水に易溶性のクエン酸水素マグネシウム水和物の結晶が析出し成長した。晶析が十分に完了した5日目に結晶をろ別して取り出し細砕した。更に、結晶を25±3℃の風で乾燥して白〜淡黄色の結晶190gを得た。尚、晶析中は溶液を撹拌しなかった。
【0022】
得られた結晶の乾燥減量(1g,150℃,5時間)を測定すると、24.1重量%であった。これはクエン酸水素マグネシウム1モルに対し水和数が3.8の水和物であることを意味している。この結晶は水に溶け易く、水に溶かした状態でpHが4.1(1g結晶/50ml水)および3.6(5g結晶/25ml水)であった。
また、結晶中のMg含有率は、日本ジャーレル・アッシュ株式会社製AA−11およびアセチレン−高圧空気の混合ガスフレームを用いた原子吸光法により、分析線波長285.21nmで測定した。
結晶中のクエン酸水素マグネシウム水和物の含有率は、分子式:MgHC6 H5 O7 ・3.8H2 Oとして、 0.05M−EDTAによる滴定結果から算出して101.12重量%であった。一方、上記の原子吸光法により求めた結晶中のMg含有率は8.66重量%であり、これから算出したクエン酸水素マグネシウム水和物の含有率は100.63重量%であった。
【0023】
更に、得られた結晶の赤外吸収スペクトルを、日本分光(株)社製FT/IR−7300を用い、臭素カリウム錠剤法により測定モード(%T)で求めた。その結果を図1に示す。
また、得られた結晶のX線回折スペクトルを、以下の条件にしたがって測定した。その結果を図2に示す。
【0024】
実施例2.
クエン酸一水和物210gをイオン交換精製水200mlに溶解させ、20〜30℃に保持した。このときのクエン酸水溶液のpHは0.5〜0.6であった。この水溶液に炭酸マグネシウム87g(MgO換算で42重量%含有)を撹拌しながら徐々に加えて反応させた。炭酸マグネシウムの添加終了後も撹拌を続け十分に反応させた。炭酸マグネシウムを溶解させた後の反応液のpHは3.0であった。この反応液をろ過して得たろ液に、水に可溶性のクエン酸水素マグネシウム水和物の微細結晶3gを種結晶として添加し均等に懸濁させた。この懸濁液を5〜10℃の低温下で4日間静置すると、水に易溶性のクエン酸水素マグネシウム水和物の結晶が析出し成長した。晶析が十分に完了した5日目に結晶をろ別して取り出して細砕した。更に、25±3℃の風で乾燥して白〜淡黄色の結晶212gを得た。尚、晶析中は溶液を撹拌していない。
この実施例2により得た結晶も、実施例1と同じく水に溶け易く、水に溶かした状態でpHが4.2 (1g/50ml水)および3.8 (5g/25ml水)であった。この結晶は乾燥減量(1g結晶,150℃,5時間)が28.3%重量であったことから判断して、クエン酸水素マグネシウムの4.7水和物(x=4.7)である。
【0025】
実施例3.
クエン酸一水和物210gをイオン交換精製水180mlに溶解させた。この水溶液に水酸化マグネシウム50gを撹拌しながら加え常温下で反応させた。このときの反応液はpHが0.5から2.7(25℃)に変化した。この反応液をろ過して得たろ液に、水に可溶性のクエン酸水素マグネシウム3gを均等に添加し、5〜10℃の低温下に静置すると結晶が析出した。この結晶をろ別し25±3℃の風で乾燥して白〜淡黄色の結晶183gを得た。
【0026】
この実施例3により得た結晶は、乾燥減量(1g,150℃,5時間)が25.1重量%であったことから判断して、クエン酸水素マグネシウムの4水和物(x=4.0)である。得られたクエン酸水素マグネシウム水和物の結晶は水に溶け易く、水に溶かした状態でpHが4.1(1g/50ml水)および3.6(5g/25ml水)であった。
結晶中のクエン酸水素マグネシウム水和物の含有率は、分子式:MgHC6 H5 O7 ・4H2 Oとして、 0.05M−EDTAによる滴定結果から算出して100.14重量%であった。また、実施例1と同じ原子吸光法により求めたMg含有率は8.47重量%であり、これから算出したクエン酸水素マグネシウム水和物の含有率は99.72重量%であった。
更に、結晶の赤外吸収スペクトルおよびX線回折スペクトルは実施例1と同機種の分析装置を用い同様に測定した。これらの結果は図3、 図4に示す。
【0027】
比較例1.
クエン酸一水和物210g(1モル量)をイオン交換精製水200mlに溶解させた。25℃に保持したクエン酸水溶液に水酸化マグネシウム62.5g(クエン酸1モル量に対し1.05倍モル量に相当する)を撹拌しながら徐々に添加して反応させた。水酸化マグネシウムを添加した後の反応液は液温が31℃でpHが3.2であった。この反応液をろ過して得たろ液に、水に易溶性のクエン酸マグネシウムの結晶3gを5〜10℃の低温下で均等に添加して静置した。これにより、白〜淡黄色の沈殿が析出した。十分に析出した時点で、沈澱をろ別し25±3℃の風で乾燥して収量268gを得た。
この比較例1により得た沈澱は、乾燥減量(1g,150℃,5時間)が27重量%であり、pHが3.8(5g/25ml水で懸濁)および4.2(1g/50ml水)であって、水には殆ど不溶であった。
【0028】
比較例2.
クエン酸一水和物210gをイオン交換精製水200mlに溶解させた。25℃に保持したクエン酸水溶液に炭酸マグネシウム96gを撹拌しながら徐々に加えて反応させた。このときの反応液は液温が37℃でpHが2.8であった。この反応液をろ過して得たろ液を60〜70℃に加熱し撹拌した。更に、反応を完結させるため、前記のろ液を攪拌しつつ液温を90℃まで上げた。反応が完結したのち、ろ液を50℃に冷却すると結晶が析出した。析出した結晶をろ別して取り出し、60℃で乾燥して白〜淡黄色の結晶260gを得た。
この比較例2により得た結晶は、乾燥減量(1g,50℃,5時間)が23重量%であった。この結晶1gを50mlの水に添加して撹拌したが殆ど溶解せず、そのときの水溶液のpHは4.9であった。
得られた結晶のX線回折結果を図5に示す。
【0029】
比較例3.
クエン酸一水和物234gをイオン交換精製水600mlに溶解させた。この水溶液のpHは0.6であった。25℃に保持したクエン酸水溶液を撹拌しながら炭酸マグネシウム110gを徐々に加えて反応させた。このときの反応液は液温が63℃でpHが3.5であった。この反応液をろ過して得たろ液を25℃で減圧濃縮することにより、反応が完結して結晶が析出した。析出した結晶をろ別して取り出し、90℃で乾燥して結晶270gを得た。
この比較例3により得た結晶は、乾燥減量(1g,150g,5時間)が7.5重量%であった。この結晶1gを水50mlに添加して撹拌したが、25℃における溶解度は水100mlに対し2g程度と良くなかった。また、そのときのpHは4.1であった。
得られた結晶のX線回折結果を図6に示す。
【0030】
溶解性および安定性試験.
実施例1,2,3および比較例1,2,3で得られた結晶の水に対する溶解性、安定性、および粉末における経時変化を比較すると、表1のようになる。
ここで、表1中の記号※1,※2,※3は以下の評価内容を表している。
※1 ・・A :水100mlに対し20g以上が溶解(25℃)。
B :水100mlに対し2〜20gが溶解(25℃)。
C :水100mlに対し2g以下で、溶解性悪い(25℃)。
※2 ・・A : 溶解時の状態で1ケ月以上変化なし。
B : 溶解時の状態で2週間まで変化なし。
C : 溶解しないか、溶解しても直ちに不溶物が析出する。
※3 ・・良 : 粉末の状態で安定である。
【0031】
上述したように、実施例1〜3で得られたクエン酸水素マグネシウム水和物は、比較例1〜3と比べて明らかなように、水に対する溶解性が高く、溶解に必要な水の量が少なくてすむ。また、粉末の状態で安定であるのは無論のこと、水溶液の状態でも変質せず安定である。
【0032】
【発明の効果】
以上詳述したように、クエン酸水素マグネシウムは様々な結晶型をもつもの(非晶質体も含め、各種水和物など)が存在するが、これまで、水によく溶けるのは非晶質体無水塩および結晶体五水和物とされてきた。
これに対し、本発明によれば、金属マグネシウムまたはマグネシウム塩類とクエン酸との反応液から、好適な晶析条件下において析出し成長した結晶が得られた。かくして得られた結晶は水和数3〜5(実数)のクエン酸水素マグネシウム水和物である。これらのクエン酸水素マグネシウム水和物は水100mlに対し20〜30gといった高い溶解度をもち、溶解に必要な水の量も少なくてすむ。しかも、常温において粉末のみならず水溶液の状態でも安定である。このように、本発明のクエン酸水素マグネシウム水和物は水易溶性であることから結晶粉末として提供できるので、医薬品原料、工業薬品原料、マグネシウム強化剤などの製剤化、例えば錠剤として使用するに有用である。
【0033】
また、本発明製法によれば、好適な晶析条件の採用により、水和数3〜5(実数)のクエン酸水素マグネシウム水和物について、これまでは成し得なかった高い水溶性を付与することができた。加えて、高純度のクエン酸水素マグネシウム水和物を収率よく簡便に製造できる。従って、経済性に富む製法を実現できたのである。
【図面の簡単な説明】
【図1】 実施例1で得られた結晶の赤外吸収スペクトルである。
【図2】 実施例1で得られた結晶のX線回折スペクトルである。
【図3】 実施例3で得られた結晶の赤外吸収スペクトルである。
【図4】 実施例3で得られた結晶のX線回折スペクトルである。
【図5】 比較例2で得られた結晶のX線回折スペクトルである。
【図6】 比較例3で得られた結晶のX線回折スペクトルである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to magnesium hydrogen citrate hydrate used for, for example, pharmaceutical raw materials, industrial chemical raw materials, magnesium fortifiers, and the like, and more particularly to water-soluble magnesium hydrogen citrate hydrate and a method for producing the same.
[0002]
[Prior art]
In general, magnesium salts of citric acid include magnesium hydrogen citrate C 6 H 6 MgO 7 and magnesium citrate C 12 H 10 Mg 3 O 14 . Most of them exist as hydrates, and their molecular formulas and structural formulas are very complex and diverse.
Any of these magnesium salts of citric acid is a transparent aqueous solution when neutralized by adding metallic magnesium or magnesium salts to an aqueous solution or suspension of citric acid in the production stage. When this aqueous solution is subjected to a process such as heating or cooling to precipitate a crystal, the crystal has various structures having various hydration numbers, citric acid numbers, or magnesium numbers depending on the crystallization conditions. Take the formula. Moreover, most of them have low solubility in water and become cloudy in water, so that it is difficult to use the obtained crystals as an aqueous solution completely dissolved again.
[0003]
On the other hand, according to the Japanese Pharmacopoeia Standards for Drugs 1997, USP official Monograph, etc., magnesium hydrogen citrate hydrate is used in the form of a liquid (aqueous solution) as an internal preparation for pretreatment in colon examination and surgery. . However, some of these liquid preparations cause precipitation with time and lack stability. Moreover, since it is a liquid agent, it must be handled in consideration of prevention of liquid leakage.
Therefore, powdered powder of magnesium hydrogen citrate is accepted as an attached standard for pharmaceutical products outside the Japanese Pharmacopoeia. Incidentally, when a magnesium salt of citric acid is used as a preparation, a powder soluble in water is used. For example, an amorphous anhydrous salt (for example, JP-A-55-108814, JP-A-Hei. No. 5-194205), or a pentahydrate of a crystal (see, for example, USP2260004, JP-A-6-228046, etc.).
[0004]
[Problems to be solved by the invention]
The present inventor is not limited to conventionally known amorphous hydrates and pentahydrates of crystals, but is easily dissolved even in a relatively small amount of water, and is stable magnesium hydrogen citrate hydrate. And a method for producing the same, and it was investigated that the change over time in the preparation was stable, and the present invention was completed.
[0005]
[Means for Solving the Problems]
In the present invention, after reacting metal magnesium or a magnesium salt having a magnesium amount of 0.6 times or more and less than 1.0 times the amount of magnesium with citric acid with respect to 1 mole of citric acid , the reaction solution is cooled to 10 ° C. or less. It is obtained by crystallization by cooling to room temperature and having a solubility in 100 ml of water at 25 ° C. of 20 g or more, and the formula: C 6 H 6 MgO 7 .xH 2 O (x: real number from 3 to 5) ) Magnesium hydrogen citrate hydrate represented by
[0006]
DETAILED DESCRIPTION OF THE INVENTION
As described above, the magnesium hydrogen citrate hydrate according to the present invention is reacted by adding metal magnesium or a magnesium salt to an aqueous solution or suspension of citric acid, and crystallizing the product from the reaction solution. It is obtained.
Citric acid used in the present invention includes not only citric acid, anhydrous citric acid and isocitric acid but also lactone which is a dehydrated product of isocitric acid.
[0007]
Further, among the magnesium metal or magnesium salts (hereinafter referred to as “magnesium raw materials”) used in the present invention, the magnesium salts may be basic salts or acidic salts, but are easily available. It is convenient to use basic salts.
Examples of such basic salts include magnesium hydroxide, magnesium carbonate, or magnesium oxide. Among them, light magnesium carbonate and heavy magnesium carbonate are exemplified. Among these, it is preferable to use magnesium hydroxide or heavy magnesium carbonate from the viewpoint of good compatibility with water and high reactivity with citric acid. Moreover, since it is reaction in aqueous solution, although it does not specifically limit as a form of magnesium salt, For example, it is desirable that it is a powder which has a fine particle diameter of 20 mesh path | pass or less because it is easy to adjust to water.
The above magnesium raw materials can be used alone or in admixture of two or more.
[0008]
As water used in the present invention, purified water such as ion-exchanged water or distilled water is used so that salts other than magnesium are not included as much as possible and pure crystals of magnesium hydrogen citrate are precipitated from water. It is preferable to use it.
[0009]
Citric acid in the present invention is used in the form of an aqueous solution or suspension. When citric acid is added to water, if the amount of water used is too small, the amount of citric acid dissolved in water will be small, so the amount of water will be 50 parts per 100 parts of citric acid (parts by weight, the same applies hereinafter). The amount is preferably 75 parts or more. On the other hand, when the amount of water used is too large, the amount of magnesium hydrogen citrate precipitated when the magnesium raw material is added decreases, so the amount of water used should be 130 parts or less with respect to 100 parts of citric acid. It is preferable that the amount is 100 parts or less.
[0010]
An aqueous solution or suspension of citric acid (hereinafter referred to as suspension aqueous solution (I)) may be in a state where the entire amount of citric acid is dissolved in water, or in a state where a part of citric acid is suspended. There may be a state in which a dissolved state and a suspended state are mixed. However, in order to allow the reaction to proceed sufficiently and to obtain homogeneous magnesium hydrogen citrate hydrate, it is preferable that the total amount of citric acid is completely dissolved in water. In preparing the suspension aqueous solution (I), the temperature of the suspension aqueous solution (I) is preferably 15 ° C. or higher, preferably about 25 ° C., in order to increase the solubility of citric acid in water. It is desirable to do.
[0011]
Subsequently, the magnesium raw material is added to the aqueous suspension (I) with stirring, whereby the reaction between citric acid and magnesium proceeds to produce magnesium hydrogen citrate hydrate, and magnesium hydrogen citrate hydrate. An aqueous solution or suspension (hereinafter referred to as suspension aqueous solution (II)) containing
[0012]
The amount of the magnesium raw material used in the present invention is 0.6 times mole amount or more, preferably 0.7 times mole amount or more, more preferably 0.75 times mole amount or more as magnesium amount with respect to 1 mole amount of citric acid. It is desirable. When the amount of the magnesium raw material used is less than 0.6 times the molar amount, the magnesium amount is absolutely insufficient, and the yield of magnesium hydrogen citrate hydrate is decreased, or citric acid is precipitated alone, which is preferable. Absent. On the other hand, in order to improve the quality of magnesium hydrogen citrate hydrate and further improve the yield with respect to citric acid, the amount of magnesium raw material used is less than 1 mol, preferably 0.98 mol or less. More preferably, the amount is 0.95 times the molar amount or less. It is not preferred that the amount of magnesium raw material used is 1-fold molar amount or more because the solubility of magnesium hydrogen citrate hydrate in water becomes extremely small.
[0013]
In the present invention, when a magnesium raw material is added to the aqueous suspension (I) of citric acid and the reaction proceeds, an aqueous suspension (II) of magnesium hydrogen citrate hydrate is obtained. This reaction is carried out in the acidic region throughout. Further, when the reaction proceeds sufficiently, both are almost completely dissolved. In this reaction, if the temperature of the aqueous suspension (I) is too low, citric acid is not completely dissolved, and as a result, the reaction does not proceed completely. Therefore, it is not preferred that the temperature of the aqueous suspension (I) is lower than 15 ° C. during the reaction, preferably 20 ° C. or higher, more preferably 25 ° C. or higher. On the other hand, if the temperature of the aqueous suspension (I) is too high, the reaction proceeds too quickly and the product is not homogeneous. Various hydrates of magnesium hydrogen citrate and magnesium citrate (two molecules of citric acid) And various hydrates of magnesium). These precipitates are insoluble in water. Therefore, the temperature of the aqueous suspension (I) during the reaction is preferably 60 ° C. or lower, more preferably 50 ° C. or lower, and further preferably 45 ° C. or lower.
[0014]
When the magnesium raw material is added to the aqueous suspension (I) of citric acid under the above conditions, the suspension of aqueous suspension (II) disappears when the reaction proceeds sufficiently, and a colorless to faint yellow transparent aqueous solution (hereinafter, Aqueous solution (I)). This aqueous solution (I) has a pH value of 2.5 (29 ° C.) to 3.3 (21 ° C.) and is in an acidic range. If crystals are precipitated during the operation or a cloudy precipitate is formed, the crystals or precipitates are not simple substances, but are often crystals or precipitates containing unintended objects. In such a case, it is necessary to remove it by filtration so that it does not mix with the desired magnesium hydrogen citrate hydrate.
[0015]
In the present invention, it is important to obtain water-soluble crystals from the aqueous solution (I) of magnesium hydrogen citrate. For that purpose, it is important to keep the aqueous solution (I) cooled at 10 ° C. or lower in the crystallization step including the crystal precipitation step and the crystal growth step. If water-soluble magnesium hydrogen citrate hydrate as a seed crystal is added to this low-temperature aqueous solution (I) in an amount of 0.5 to 2.0% by weight based on the amount of citric acid charged, the desired magnesium hydrogen citrate hydrate The product can be obtained with higher yield. The seed crystal to be added may be water-soluble anhydrous magnesium citrate.
When the seed crystal is added and gently stirred, the aqueous solution (I) becomes a suspension (hereinafter referred to as suspension (III)). This suspension (III) is cooled and held at 4 to 5 ° C. and allowed to stand for 25 to 50 hours. During this time, it is important that no mixing is performed by stirring. Thus, the end point of the crystallization process is defined as the point at which the crystal has grown sufficiently and no more crystal is observed.
[0016]
What precipitated during this period has a crystal form, and no cloudy precipitate is present. A preferable crystallization temperature for obtaining such crystals is 10 ° C. or lower. If the solution temperature at the time of crystallization exceeds 10 ° C., the seed crystal added in the next step is dissolved and is no longer useful. However, the solution temperature should be as low as possible, but at least the freezing temperature of the solution needs to be higher.
Incidentally, when the suspension (III) being crystallized is stirred, water-insoluble fine crystals and a cloudy precipitate are deposited. On the other hand, in the present invention, the crystal mass is allowed to stand still without stirring, and then separated from the mother liquor, taken out and pulverized, and then blown and dried. The preferable drying temperature is 50 ° C. or lower, more preferably 35 ° C. or lower, and most preferably 25 ° C. or lower. When the drying temperature exceeds 50 ° C., the hydration number is affected and the solubility of the crystals in water may be reduced.
[0017]
The obtained crystals are white to light yellow, and are magnesium hydrogen citrate hydrate that dissolves in a relatively small amount of water, up to 5 times the amount even in a low temperature atmosphere. The hydration number of this magnesium hydrogen citrate hydrate varies slightly depending on the concentration of the raw material used in the reaction, that is, the reaction ratio of citrate ions and magnesium ions and the drying temperature, but it is 3 per 1 mole of magnesium hydrogen citrate. ~ 5 (real number).
[0018]
The crystals obtained as described above depend on the concentration of the solute in the solution, or when the solute concentration is constant, the cooling temperature, the composition of magnesium hydrogen citrate hydrate added as a seed crystal, or the drying of the crystals. Depending on the temperature, the crystal form and hydration number differ, and as a result, the solubility in water also differs.
Therefore, in crystallization of the reaction product in the present invention, 0.02 to 0.04% by weight of water-soluble magnesium hydrogen citrate hydrate is used as a seed crystal in a low-temperature saturated aqueous solution based on the total amount charged. By adding and allowing to stand at 3 to 10 ° C., the desired crystals of magnesium hydrogen citrate hydrate can be obtained. The seed crystal may be added in an amount sufficient to form crystal nuclei, and is preferably as small as possible.
[0019]
The thus obtained magnesium hydrogen citrate hydrate of the present invention has a hydration number x that varies depending on the crystallization conditions, but C 6 H 6 MgO 7 .xH 2 O (x: real number from 3 to 5). 20 g or more dissolved in 100 ml of water at 25 ° C. and in a stable state (pH = 3.5 to 4.5), and the magnesium content is 8.0 to 9.1 wt% (water Japanese equivalent).
[0020]
【Example】
Next, although the magnesium hydrogen citrate hydrate of the present invention and the production method thereof will be described in more detail based on the following examples and comparative examples, the present invention is not limited to such examples.
[0021]
Example 1.
210 g of citric acid monohydrate was dissolved in 200 ml of ion-exchange purified water and kept at 20-30 ° C. At this time, the citric acid aqueous solution may be suspended. At this time, the pH of the aqueous citric acid solution was 0.5 to 0.6. To this citric acid aqueous solution, 45 g of magnesium hydroxide was gradually added with stirring. Stirring was continued after the addition of magnesium hydroxide was completed, and the reaction was sufficiently performed. The pH of the reaction solution after dissolving magnesium hydroxide was 2.6. 2 g of fine crystals of magnesium hydrogen citrate hydrate, which is easily soluble in water, were added as seed crystals to the filtrate obtained by filtering this reaction solution, and suspended uniformly. When this suspension was allowed to stand at a low temperature of 5 to 10 ° C. for 4 days, crystals of magnesium hydrogen citrate hydrate, which was readily soluble in water, precipitated and grew. On the fifth day when the crystallization was sufficiently completed, the crystals were separated by filtration and pulverized. Further, the crystals were dried with a wind of 25 ± 3 ° C. to obtain 190 g of white to pale yellow crystals. During the crystallization, the solution was not stirred.
[0022]
The loss on drying (1 g, 150 ° C., 5 hours) of the obtained crystals was measured and found to be 24.1% by weight. This means that the hydrate number is 3.8 with respect to 1 mole of magnesium hydrogen citrate. The crystals were easily soluble in water, and pH in the dissolved state was 4.1 (1 g crystal / 50 ml water) and 3.6 (5 g crystal / 25 ml water).
Further, the Mg content in the crystal was measured at an analytical line wavelength of 285.21 nm by an atomic absorption method using a mixed gas flame of AA-11 manufactured by Nippon Jarrell-Ash Co., Ltd. and acetylene-high pressure air.
The content of magnesium hydrogen citrate hydrate in the crystal was 101.12% by weight calculated from the titration result with 0.05M-EDTA as the molecular formula: MgHC 6 H 5 O 7 .3.8H 2 O. It was. On the other hand, the Mg content in the crystal determined by the atomic absorption method was 8.66% by weight, and the content of magnesium hydrogen citrate hydrate calculated therefrom was 100.63% by weight.
[0023]
Furthermore, the infrared absorption spectrum of the obtained crystal was determined in the measurement mode (% T) by the potassium bromine tablet method using FT / IR-7300 manufactured by JASCO Corporation. The result is shown in FIG.
Moreover, the X-ray diffraction spectrum of the obtained crystal was measured according to the following conditions. The result is shown in FIG.
[0024]
Example 2
210 g of citric acid monohydrate was dissolved in 200 ml of ion-exchange purified water and kept at 20-30 ° C. At this time, the pH of the aqueous citric acid solution was 0.5 to 0.6. To this aqueous solution, 87 g of magnesium carbonate (containing 42% by weight in terms of MgO) was gradually added with stirring to react. Stirring was continued after the addition of magnesium carbonate and the reaction was sufficiently performed. The pH of the reaction solution after dissolving magnesium carbonate was 3.0. 3 g of fine crystals of water-soluble magnesium hydrogen citrate hydrate were added as seed crystals to the filtrate obtained by filtering this reaction solution and suspended uniformly. When this suspension was allowed to stand at a low temperature of 5 to 10 ° C. for 4 days, crystals of magnesium hydrogen citrate hydrate, which was readily soluble in water, precipitated and grew. On the 5th day when the crystallization was sufficiently completed, the crystals were separated by filtration and ground. Furthermore, it was dried with a wind of 25 ± 3 ° C. to obtain 212 g of white to pale yellow crystals. Note that the solution was not stirred during crystallization.
The crystals obtained in Example 2 were also easily soluble in water as in Example 1, and had a pH of 4.2 (1 g / 50 ml water) and 3.8 (5 g / 25 ml water) when dissolved in water. . This crystal is 4.7 hydrate of magnesium hydrogen citrate (x = 4.7) judging from the loss on drying (1 g crystal, 150 ° C., 5 hours) was 28.3% by weight. .
[0025]
Example 3
210 g of citric acid monohydrate was dissolved in 180 ml of ion exchange purified water. To this aqueous solution, 50 g of magnesium hydroxide was added with stirring and reacted at room temperature. At this time, the pH of the reaction solution changed from 0.5 to 2.7 (25 ° C.). When 3 g of magnesium hydrogen citrate soluble in water was evenly added to the filtrate obtained by filtering the reaction solution and allowed to stand at a low temperature of 5 to 10 ° C., crystals were precipitated. The crystals were separated by filtration and dried with a wind of 25 ± 3 ° C. to obtain 183 g of white to pale yellow crystals.
[0026]
Judging from the fact that the crystal obtained in Example 3 had a loss on drying (1 g, 150 ° C., 5 hours) of 25.1 wt%, magnesium hydrogen citrate tetrahydrate (x = 4. 0). The obtained magnesium hydrogen citrate hydrate crystals were easily soluble in water, and pH in the dissolved state was 4.1 (1 g / 50 ml water) and 3.6 (5 g / 25 ml water).
The content of magnesium hydrogen citrate hydrate in the crystal was 100.14% by weight calculated from the titration result with 0.05M-EDTA as the molecular formula: MgHC 6 H 5 O 7 .4H 2 O. The Mg content determined by the same atomic absorption method as in Example 1 was 8.47% by weight, and the content of magnesium hydrogen citrate hydrate calculated from this was 99.72% by weight.
Furthermore, the infrared absorption spectrum and X-ray diffraction spectrum of the crystal were measured in the same manner using an analyzer of the same model as in Example 1. These results are shown in FIGS.
[0027]
Comparative Example 1
Citric acid monohydrate (210 g, 1 mol) was dissolved in 200 ml of ion exchange purified water. 62.5 g of magnesium hydroxide (corresponding to 1.05 times mole amount with respect to 1 mole amount of citric acid) was gradually added to the aqueous citric acid solution kept at 25 ° C. with stirring to react. The reaction liquid after adding magnesium hydroxide had a liquid temperature of 31 ° C. and a pH of 3.2. To the filtrate obtained by filtering this reaction solution, 3 g of magnesium citrate crystals that are readily soluble in water were evenly added at a low temperature of 5 to 10 ° C. and left to stand. Thereby, a white to pale yellow precipitate was deposited. When fully precipitated, the precipitate was filtered off and dried in a wind of 25 ± 3 ° C. to obtain a yield of 268 g.
The precipitate obtained in Comparative Example 1 has a loss on drying (1 g, 150 ° C., 5 hours) of 27% by weight, a pH of 3.8 (suspended in 5 g / 25 ml water) and 4.2 (1 g / 50 ml). Water) and almost insoluble in water.
[0028]
Comparative Example 2
210 g of citric acid monohydrate was dissolved in 200 ml of ion exchange purified water. To the citric acid aqueous solution maintained at 25 ° C., 96 g of magnesium carbonate was gradually added with stirring to react. The reaction solution at this time had a solution temperature of 37 ° C. and a pH of 2.8. The filtrate obtained by filtering this reaction solution was heated to 60 to 70 ° C. and stirred. Furthermore, in order to complete the reaction, the liquid temperature was raised to 90 ° C. while stirring the filtrate. After the reaction was completed, the filtrate was cooled to 50 ° C. to precipitate crystals. The precipitated crystals were separated by filtration and dried at 60 ° C. to obtain 260 g of white to pale yellow crystals.
The crystal obtained in Comparative Example 2 had a loss on drying (1 g, 50 ° C., 5 hours) of 23% by weight. 1 g of this crystal was added to 50 ml of water and stirred, but hardly dissolved, and the pH of the aqueous solution at that time was 4.9.
The X-ray diffraction result of the obtained crystal is shown in FIG.
[0029]
Comparative Example 3
234 g of citric acid monohydrate was dissolved in 600 ml of ion-exchange purified water. The pH of this aqueous solution was 0.6. While stirring the aqueous citric acid solution maintained at 25 ° C., 110 g of magnesium carbonate was gradually added to cause the reaction. The reaction liquid at this time had a liquid temperature of 63 ° C. and a pH of 3.5. The filtrate obtained by filtering this reaction solution was concentrated under reduced pressure at 25 ° C., whereby the reaction was completed and crystals were precipitated. The precipitated crystals were separated by filtration and dried at 90 ° C. to obtain 270 g of crystals.
The crystal obtained in Comparative Example 3 had a loss on drying (1 g, 150 g, 5 hours) of 7.5% by weight. 1 g of this crystal was added to 50 ml of water and stirred, but the solubility at 25 ° C. was not as good as 2 g for 100 ml of water. The pH at that time was 4.1.
The X-ray diffraction result of the obtained crystal is shown in FIG.
[0030]
Solubility and stability test.
Table 1 compares the solubility of the crystals obtained in Examples 1, 2, 3 and Comparative Examples 1, 2, 3 with respect to water, stability, and changes over time in the powder.
Here, symbols * 1, * 2 and * 3 in Table 1 represent the following evaluation contents.
* 1 ・ ・ A: Dissolve 20g or more in 100ml of water (25 ℃).
B: 2 to 20 g is dissolved in 100 ml of water (25 ° C.).
C: Less than 2 g per 100 ml of water, poor solubility (25 ° C.).
* 2 ・ ・ A: No change for more than 1 month when dissolved.
B: No change until 2 weeks in the dissolved state.
C: Insoluble matter does not dissolve or precipitates immediately after dissolution.
* 3 ・ ・ Good: Stable in powder form.
[0031]
As described above, the magnesium hydrogen citrate hydrate obtained in Examples 1 to 3 has a high solubility in water as is clear compared with Comparative Examples 1 to 3, and the amount of water required for dissolution. Less. Of course, it is stable in a powder state, and it is stable without changing in the state of an aqueous solution.
[0032]
【The invention's effect】
As described in detail above, magnesium hydrogen citrate has various crystal types (including amorphous hydrates and various hydrates), but until now, it is amorphous that dissolves well in water. Anhydrous salts and crystalline pentahydrate.
On the other hand, according to the present invention, crystals that were precipitated and grown under suitable crystallization conditions were obtained from a reaction solution of metallic magnesium or magnesium salts and citric acid. The crystals thus obtained are magnesium hydrogen citrate hydrate having a hydration number of 3 to 5 (real number). These magnesium hydrogen citrate hydrates have a high solubility of 20 to 30 g per 100 ml of water, and the amount of water required for dissolution can be reduced. Moreover, it is stable not only in powder but also in an aqueous solution at normal temperature. As described above, since the magnesium hydrogen citrate hydrate of the present invention is readily soluble in water, it can be provided as a crystalline powder. Useful.
[0033]
Further, according to the production method of the present invention, by adopting suitable crystallization conditions, high water solubility that could not be achieved so far is imparted to hydrated magnesium hydrogen citrate hydrate having 3 to 5 (real number). We were able to. In addition, high-purity magnesium hydrogen citrate hydrate can be easily produced with good yield. Therefore, an economical manufacturing method could be realized.
[Brief description of the drawings]
1 is an infrared absorption spectrum of the crystal obtained in Example 1. FIG.
2 is an X-ray diffraction spectrum of the crystal obtained in Example 1. FIG.
3 is an infrared absorption spectrum of the crystal obtained in Example 3. FIG.
4 is an X-ray diffraction spectrum of the crystal obtained in Example 3. FIG.
5 is an X-ray diffraction spectrum of the crystal obtained in Comparative Example 2. FIG.
6 is an X-ray diffraction spectrum of the crystal obtained in Comparative Example 3. FIG.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14250498A JP3981467B2 (en) | 1998-05-25 | 1998-05-25 | Magnesium hydrogen citrate hydrate and process for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14250498A JP3981467B2 (en) | 1998-05-25 | 1998-05-25 | Magnesium hydrogen citrate hydrate and process for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11335377A JPH11335377A (en) | 1999-12-07 |
| JP3981467B2 true JP3981467B2 (en) | 2007-09-26 |
Family
ID=15316888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14250498A Expired - Lifetime JP3981467B2 (en) | 1998-05-25 | 1998-05-25 | Magnesium hydrogen citrate hydrate and process for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3981467B2 (en) |
-
1998
- 1998-05-25 JP JP14250498A patent/JP3981467B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11335377A (en) | 1999-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reinitzer | Contributions to the knowledge of cholesterol | |
| US3916004A (en) | Process for producing dopa preparation | |
| CN107619383B (en) | A kind of method for preparing carbaspirin calcium microcrystalline powder | |
| CN108546251A (en) | The novel crystal forms of prothioconazoles | |
| US9845284B1 (en) | Method of obtaining complex acidic salts of divalent metals and dicarboxylic acids | |
| JP2001522344A (en) | Manufacturing method of calcium borate | |
| JP3981467B2 (en) | Magnesium hydrogen citrate hydrate and process for producing the same | |
| JP4177471B2 (en) | Method for producing mixed glucosamine salt | |
| JP2676521B2 (en) | Method for producing quinolone carboxylic acid compound type I crystals | |
| JP3574185B2 (en) | Anhydrotrimagnesium citrate and its preparation | |
| CA2771635C (en) | Crystalline levofolinic acid and process for its preparation | |
| CN106977552B (en) | The preparation method of citric acid ferric pyrophosphate mixed air EDM | |
| KR102951493B1 (en) | Improved synthesis and purification method of citrulline | |
| CN115894394A (en) | A method for preparing high-purity DOTA | |
| US6534674B2 (en) | Crystalline disodium pamidronate hydrate and process for preparing it | |
| CN114195662B (en) | Method for synthesizing high-content calcium disodium edetate | |
| JP2018104312A (en) | Imidazopyrroloquinoline salt and method for producing the same, and pharmaceutical, cosmetic and food | |
| CN107698563B (en) | Method for preparing neratinib maleate crystal form | |
| JP2004091442A (en) | Water-soluble magnesium citrate salt hydrate and method for producing the same | |
| KR100659330B1 (en) | Method for preparing high purity water soluble calcium using crystallization | |
| JP2001181231A (en) | Organic acid titanium alkali metal salt and method for producing the same | |
| EP3149014B1 (en) | Process for producing crystalline dtpmp | |
| JPH04305590A (en) | Manganese oligomer containing main group element | |
| SU1726370A1 (en) | Method of tellurium dioxide preparation | |
| CN120698980A (en) | Nicotine ditartaric acid dihydrate and single crystal preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041118 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061121 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070605 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070702 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100706 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110706 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120706 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130706 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |